23andMe CEO and Co-Founder Anne Wojcicki talks with WJS’s Jason Dean about how her company reworked its core genetic test, and its next steps as a direct-to-consumer business. They speak at the WSJDLive conference in Laguna Beach, Calif.
Subscribe to the WSJ channel here:
http://bit.ly/14Q81Xy
More from the Wall Street Journal:
Visit WSJ.com: http://www.wsj.com
Follow WSJ on Facebook: http://www.facebook.com/wsjvideo
Follow WSJ on Google+: https://plus.google.com/+wsj/posts
Follow WSJ on Twitter: https://twitter.com/WSJvideo
Follow WSJ on Instagram: http://instagram.com/wsj
Follow WSJ on Pinterest: http://www.pinterest.com/wsj/
source
The women on the 23andMe commercials sure make it sound like their newly discovered ethnic heritage is a heck of a lot more fundamental to who they are as people than what Wojcicki is stating here.
$200 canadian and the data will be stored on the cloud so Google may keep, use and sell my data.
No I rather get paid for this or else make it free, I'll probably take it
It seems likely that with genetic testing one could actually find genetic downside risk for medications. Meaning, slightly more specifically, that one could figure out what populations are more likely to suffer adverse side effects from a particular treatment.